Vimarsana
Biggest News Aggregation in the World

Page 10 - Chief Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chief Science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chief Science Today - Breaking & Trending Today

Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel - Vimarsana News

Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel

 Marvel Biosciences Corp.  and its wholly owned subsidiary, Marvel Biotechnology Inc. , is pleased to announce a collaboration with Professor Emmanuel Planel of Laval University to study the acute...

Kaival Brands Appoints Executive Chairman Barry Hopkins as Interim Chief Executive Officer and President - Philip Morris Intl (NYSE:PM), Kaival Brands Innovations (NASDAQ:KAVL) - Vimarsana News

Kaival Brands Appoints Executive Chairman Barry Hopkins as Interim Chief Executive Officer and President - Philip Morris Intl (NYSE:PM), Kaival Brands Innovations (NASDAQ:KAVL)

GRANT-VALKARIA, Fla., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) ("Kaival Brands," the "Company," or "we") today announced that it has expanded the

iTWire - Startup Mesh Ai launches 'first AI-enabled' workplace mental health solution for Microsoft Teams and Microsoft 365 - Vimarsana News

iTWire - Startup Mesh Ai launches 'first AI-enabled' workplace mental health solution for Microsoft Teams and Microsoft 365

Australian startup Mesh Ai has announced the release of Simpatico Teams, a “pioneering AI-driven mental health application” for Microsoft Teams, Micro...

Source: itwire.com
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide - Vimarsana News

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

TORONTO, Dec. 13, 2023 -- Arch Biopartners Inc., , announced today it has submitted a Clinical Trial Application to Health Canada to obtain permission to proceed with a Phase II trial for LSALT...

Expert Discusses Biosignature Model's Potential in Predicting Therapy Response in Early-Stage Breast Cancer - Vimarsana News

Expert Discusses Biosignature Model's Potential in Predicting Therapy Response in Early-Stage Breast Cancer

Troy Bremer, PhD, chief ocientific Officer at PreludeDx, discusses biosignature model and it's potential in predicting radiation therapy response for those with early-stage invasive breast cancer.

Related Topics:
Troy BremerChief Science